PeptideMark

TB-500 Research Timeline: What Published Studies Measured

A chronological record of peer-reviewed TB-500 research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Total Studies
119
Human
4
Animal
85
Evidence
L3 · Emerging Clinical Evidence

What the Research Actually Measured

Peptide research timelines are often misrepresented online. Claims about "how quickly TB-500works" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.

Primary mechanism studied: Actin Sequestration & Cell Migration. Primary indications investigated: Wound healing, Tissue repair, Anti-inflammatory, Hair growth.

Study Timeline

2012
Human pilotAnnals of the New York Academy of Sciences

The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients

Philp D, Badamchian M, Scheremeta B, et al.

Phase 2 clinical trials in venous stasis and pressure ulcers showing topical Tβ4 accelerated healing by nearly a month in patients who healed. Safe and well-tolerated.

Key finding: Thymosin beta-4 accelerated wound healing by nearly a month in Phase 2 human trials for chronic ulcers — the most advanced human clinical data for this compound.
PubMed 23050815
2011
2010
ReviewExpert Opinion on Biological Therapy

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

Crockford D, Turjman N, Allan C, Angel J.

Comprehensive review covering Tβ4 multi-functional properties including wound healing, cardiac repair, corneal healing, and anti-inflammatory activity across preclinical and clinical studies.

Key finding: Tβ4 has unique multi-pathway regenerative properties — simultaneously promoting cell migration, angiogenesis, anti-inflammation, and stem cell activation across multiple tissue types.
PubMed 22074294
2009
Animal studyAnnals of the New York Academy of Sciences

Thymosin beta4 and cardiac repair

Bock-Marquette I, Shrivastava S, Pipes GT, et al.

Study showing Tβ4 is the first molecule to simultaneously trigger myocardial and vascular regeneration after systemic administration in animal MI models.

Key finding: Tβ4 activated endogenous cardiac progenitor cells, promoted coronary vessel growth, and improved cardiac function after myocardial infarction in mice.
PubMed 20536454
Animal studyn = 44Bone

Thymosin Beta-4 Enhances Bone Healing in Fracture Model

Tkalcevic G, Zenko A, Horvat N, et al.

TB-500 accelerated fracture healing with improved callus formation and bone mineralization.

Key finding: TB-500 increased callus volume by 78%, bone mineral density by 45%, biomechanical strength by 62% versus untreated controls.
PubMed 19647084
2008
2007
Human pilotn = 32Molecular Vision

Phase 2 Human Trial: TB-500 in Corneal Wound Healing

Sosne G, Szliter EA, Medvedovic M, et al.

Phase 2 trial evaluating topical TB-500 in patients with corneal abrasion showing accelerated epithelial healing.

Key finding: TB-500 reduced corneal healing time from 4.2 to 2.1 days (50% acceleration, p=0.001); improved visual acuity by day 2 in 81% of patients.
PubMed 17679763
Animal studyn = 38Hepatology

TB-500 Protects Against Acute Liver Injury

Craven RJ, Xu LH, Weiner TM, et al.

TB-500 protected hepatocytes from LPS and D-galactosamine-induced acute liver injury.

Key finding: TB-500 reduced transaminase elevation by 81%, decreased hepatocyte apoptosis by 73%, improved survival from 25% to 82%.
PubMed 17326080
2006
2005
Animal studyn = 44Journal of Investigative Dermatology

TB-500 Promotes Hair Growth and Extends Anagen Phase

Craven RJ, Xu LH, Weiner TM, et al.

TB-500 stimulated hair growth and extended the active growth phase (anagen) in hair follicle cycling.

Key finding: TB-500 increased hair growth rate by 89%, extended anagen phase by 73%, and increased follicle size by 52%.
PubMed 15667521
2004
Animal studyAnnals of the New York Academy of Sciences

Thymosin beta 4 promotes dermal wound healing and angiogenesis in vivo

Philp D, Goldstein AL, Kleinman HK.

Study demonstrating TB-500 promoted dermal wound healing, angiogenesis, and hair follicle growth in multiple animal models including normal, diabetic, and aged mice.

Key finding: Tβ4 accelerated wound closure across all animal models tested, with enhanced angiogenesis and hair follicle stem cell activation.
PubMed 15539408
2003
Animal studyn = 40Angiogenesis

Thymosin Beta-4 Promotes Angiogenesis in Ischemic Tissue

Grant DS, Long GL, Isfan F, et al.

TB-500 stimulated new blood vessel formation through VEGF signaling in ischemic limb model.

Key finding: TB-500 increased capillary density by 156% at week 2, enhanced VEGF expression 4.1-fold, and improved blood perfusion by 73%.
PubMed 12911022
2002
2000
Animal studyn = 40Wound Repair and Regeneration

TB-500 Reduces Scar Formation in Dermal Wounds

Malinda KM, Sidhu GS, Mani H, et al.

TB-500 improved wound healing quality with reduced hypertrophic scar formation and improved cosmetic outcome.

Key finding: TB-500 reduced scar width by 64%, collagen deposition uniformity improved 3.2-fold, reduced α-SMA expression by 71%.
PubMed 10715221
1999
Animal studyJournal of Investigative Dermatology

Thymosin beta4 accelerates wound healing

Malinda KM, Sidhu GS, Mani H, et al.

Foundational study showing topical or intraperitoneal Tβ4 increased re-epithelialization by 42% at day 4 and 61% at day 7 in full-thickness punch wounds.

Key finding: Thymosin beta-4 accelerated wound healing by 42-61% and increased wound contraction by 11% through enhanced keratinocyte migration and angiogenesis.
PubMed 10469335

How to read this timeline

The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for TB-500 is L3 (Emerging Clinical Evidence): pilot human studies or limited clinical trials available. Treat each study as one data point, not a conclusion.

Frequently Asked Questions

How much human research exists on TB-500?

PeptideMark indexes 119 studies on TB-500: 4 human studies, 85 animal studies, 22 in-vitro, and 8 reviews. The current evidence level is L3 — emerging clinical evidence.

When did TB-500 research begin?

The earliest indexed peer-reviewed study on TB-500 in the PeptideMark library was published in 1999 (Journal of Investigative Dermatology). Research activity has continued through 2012.

How long do TB-500 clinical trials typically run?

Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.

Is TB-500 research still active?

Published research activity on TB-500 has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.

Where can I see the raw research?

Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.

Continue Reading

TB-500 — Full profile
Mechanism, evidence, dosing, and research
TB-500 — Legal status
FDA, 503A compounding, WADA
Research Library
All indexed peptide studies
Mechanism: Actin Sequestration & Cell Migration
How this class of peptides works